3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
OTHER
5
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Neoplasm Metastasis
3
Stomatitis
2
Stomach Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Trauma, Nervous System
1
Thromboembolism
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Lipoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Intracranial Hemorrhages
1
Interventions
Capecitabine
77
pembrolizumab
70
Oxaliplatin
68
Cisplatin
56
Fluorouracil
52
Paclitaxel
41
Trastuzumab
37
Nivolumab
35
Leucovorin
27
Docetaxel
27
Irinotecan
22
Ramucirumab
20
Gemcitabine
15
Bevacizumab
15
S 1 (combination)
14
Carboplatin
13
atezolizumab
12
apatinib
12
fludarabine
11
Cyclophosphamide
11
tislelizumab
10
Drug Therapy
10
Injections
8
130-nm albumin-bound paclitaxel
8
trastuzumab deruxtecan
7
durvalumab
7
Ipilimumab
7
Folfox protocol
7
Albumin-Bound Paclitaxel
7
titanium silicide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Stomach Neoplasms
×
Saline Solution
×
Clear all
NCT03221426
2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3
Completed
1,007 enrolled
25 charts
NCT04882241
2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3
Completed
120 enrolled
17 charts